Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The NDA filing is supported by results from the phase III evERA Breast Cancer study
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Subscribe To Our Newsletter & Stay Updated
